The EU H2020 KATY's project official kick-off started yesterday, February 9, 2021, with a virtual meeting attended by Cátia Pesquita, LASIGE integrated researcher and the Principal Investigator of the LASIGE team.

The newly launched KATY (Knowledge At the Tip of Your fingers: Clinical Knowledge for Humanity) project has set out to build a precise personalized medicine system empowered by Artificial Intelligence (AI).

The novel AI tool aims to predict the response of kidney cancer to targeted therapies and identify the molecular evidence to support these predictions. Most importantly, the KATY system will offer human interpretable knowledge that clinicians and clinical researchers can trust, adequately evaluate and effectively use in their everyday working routine.

KATY’s AI-based personalized medicine tool is at the cutting edge of new treatments for cancer and may bring targeted therapies to the next level. Using KATY’s AI-based models in cancer care will boost the use of tailored, targeted treatments and answer a problem encountered daily by clinicians: Which targeted therapy would be the most suitable for a specific patient? Therefore, the project is striving to build a trustworthy, easy-to-understood tool for medical professionals to make better therapy decisions for people with cancer.

In short, the goals of the KATY project are to:

• reduce the burden of disease for renal cancer patients,
• apply existing treatments in a more targeted way,
• identify new evidence on the predictive value of AI solutions,
• enhance the diagnostic capacity for complex diseases.

This project is led by Università degli Studi di Roma “Tor Vergata” (Italy), involves Twenty internationally-renowned institutions from 11 countries: Austria, France, Germany, Greece, Italy, Poland, Portugal, Spain, Sweden, Ukraine, United Kingdom.

More information: here.